Boston Scientific Co. (NYSE:BSX) Position Boosted by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG grew its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 40.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 73,096 shares of the medical equipment provider's stock after acquiring an additional 21,173 shares during the period. Bank Pictet & Cie Europe AG's holdings in Boston Scientific were worth $6,529,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Creative Planning lifted its position in shares of Boston Scientific by 7.7% during the 3rd quarter. Creative Planning now owns 204,208 shares of the medical equipment provider's stock worth $17,113,000 after buying an additional 14,663 shares in the last quarter. Global Retirement Partners LLC boosted its stake in Boston Scientific by 11.5% in the 3rd quarter. Global Retirement Partners LLC now owns 4,370 shares of the medical equipment provider's stock worth $366,000 after purchasing an additional 449 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in Boston Scientific by 2.0% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 172,494 shares of the medical equipment provider's stock worth $14,455,000 after purchasing an additional 3,433 shares in the last quarter. CHB Investment Group LLC bought a new position in Boston Scientific in the 3rd quarter worth about $2,900,000. Finally, V Square Quantitative Management LLC grew its stake in Boston Scientific by 20.8% in the 3rd quarter. V Square Quantitative Management LLC now owns 11,133 shares of the medical equipment provider's stock worth $933,000 after buying an additional 1,914 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on BSX. JPMorgan Chase & Co. lifted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a research note on Monday, December 16th. Stifel Nicolaus raised their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Raymond James increased their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research note on Thursday, February 6th. Barclays boosted their target price on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Finally, UBS Group raised their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research report on Friday, February 7th. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $107.39.

Insider Activity at Boston Scientific

In related news, EVP John Bradley Sorenson sold 1,201 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the sale, the executive vice president now directly owns 25,443 shares in the company, valued at approximately $2,704,845.33. This trade represents a 4.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the company's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares of the company's stock, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 158,517 shares of company stock worth $16,165,168. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Shares of Boston Scientific stock traded up $0.28 during trading hours on Wednesday, hitting $105.63. 4,304,879 shares of the company were exchanged, compared to its average volume of 6,051,952. Boston Scientific Co. has a 1 year low of $65.33 and a 1 year high of $107.17. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average of $97.09 and a 200-day moving average of $88.82. The stock has a market capitalization of $155.68 billion, a price-to-earnings ratio of 84.50, a P/E/G ratio of 2.81 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.